Insmed Incorporated (INSM) Gained from Its Lead Product ARIKAYCE

Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Mid Cap Fund”.  A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. US equities ended a record year with robust fourth-quarter gains. The Fund’s Investor Class, ARTMX, delivered -0.44%, the Advisor Class, APDMX, delivered -0.37%, and the Institutional Class, APHMX, delivered -0.35% in the fourth quarter compared to -3.70% for the Russell Midcap® Growth Index. Continued strength in information technology (IT) and health care contributed to the performance during the quarter. Please review the Fund’s top five holdings to gain insights into their key selections for 2025.

In its fourth-quarter 2025 investor letter, Artisan Mid Cap Fund highlighted stocks like Insmed Incorporated (NASDAQ:INSM). Insmed Incorporated (NASDAQ:INSM) is a biotechnology company specializing in developing therapies for serious and rare diseases. On February 23, 2026, Insmed Incorporated (NASDAQ:INSM) stock closed at $159.03 per share. One-month return of Insmed Incorporated (NASDAQ:INSM) was -2.22%, and its shares gained 105.20% over the past 52 weeks. Insmed Incorporated (NASDAQ:INSM) has a market capitalization of $33.917 billion.

Artisan Mid Cap Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its fourth quarter 2025 investor letter:

"Our top contributors in Q4 were Argenx, Coherent and Insmed Incorporated (NASDAQ:INSM). Insmed is a biotechnology company focused on pulmonary diseases. Its lead product, ARIKAYCE®, continues to perform well, with management raising full-year revenue guidance following 22% YoY growth. The company also reported a strong launch for Brinsupri™ (brensocatib), the first approved therapy for non-cystic fibrosis bronchiectasis, generating $28 million in initial sales with more than 2,500 patients and 1,700 prescribers. We remain encouraged by Insmed’s execution and believe Brinsupri™ is likely to drive a substantial profit cycle in the coming quarters and years."

Insmed Incorporated (NASDAQ:INSM) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 74 hedge fund portfolios held Insmed Incorporated (NASDAQ:INSM) at the end of the fourth quarter, up from 73 in the previous quarter. While we acknowledge the potential of Insmed Incorporated (NASDAQ:INSM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Insmed Incorporated (NASDAQ:INSM) and shared billionaire Stanley Druckenmiller’s best stock picks. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.